The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Exploiting DNA damage in colorectal cancer to improve patient survival
Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, comments on how recent clinical trials have focused on the exploitation of DNA damage in microsatellite stable colorectal cancer (MSS CRC) via different agents with the aim of improving survival outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
